- Statistisches Bundesamt, Fachserie 12, Reihe 6.2.1, über www.gbe-bund.de.
- Wille E, Popp M: Gastroenterologische Kernleistungen unter gesundheitsökonomischen Aspekten 2013. Gutachten im Auftrag der DGVS.
- Lynen Jansen P, Preiss JC, Muche-Borowski C, et al.: Das Leitlinienprogramm der DGVS. Z Gastroenterol 2013; 51: 643–50.
- AWMF Ad-hoc-Kommission „Gemeinsam Klug Entscheiden“. Manual „Entwicklung von Empfehlungen im Rahmen der Initiative Gemeinsam Klug Entscheiden“ – Konsultationsfassung. www.awmf.org/medi zin-versorgung/gemeinsam-klugentscheiden. html.
- Riphaus A, Wehrmann T, Hausmann J, et al.: Update S3-Leitlinie„Sedierungindergastrointestinalen Endoskopie“ 2014. Z Gastroenterol 2015; 53: 802–42.
- Dumonceau JM, Riphaus A, Aparicio JR, et al.: European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates, and the European Society of Anaesthesiology Guideline: Non-anaesthesiologist administration of propofol for GI endoscopy. Eur J Anaesthesiol 2010; 27: 1016–30.
- Dumonceau JM, Riphaus A, Aparicio JR, et al.: European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates, and the European Society of Anaesthesiology Guideline: Non-anesthesiologist administration of propofol for GI endoscopy. Endoscopy 2010; 42: 960–74.
- Jain R, Ikenberry SO, Anderson MA, et al.: Minimum staffing requirements for the performance of GI endoscopy. Gastrointest Endosc 2010; 72: 469–70.
- Vargo JJ, Cohen LB, Rex DK, et al.: Position statement: Nonanesthesiologist administration of propofol for GI endoscopy. Gastroenterology 2009; 137: 2161–7.
- Seufferlein T, Porzner M, Becker T, et al.: S3-Leitlinie exokrines Pankreaskarzinom. Z Gastroenterol 2013; 51: 1395–440.
- Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative- intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007; 297: 267–77.
- Ueno H, Kosuge T, Matsuyama Y, et al.: A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908–15.
- Stocken DD, Buchler MW, Dervenis C, et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372–81.
- Neoptolemos JP, Stocken DD, Bassi C, et al.: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. Jama 2010; 304: 1073–81.
- Yoshitomi H, Togawa A, Kimura F, et al.: A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008; 113: 2448–56.
- Greten TF, Malek NP, Schmidt S, et al.: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2013; 51: 1269–326.
- Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2.
- Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417–22.
- Chen JG, Parkin DM, Chen QG, et al.: Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204–9.
- Singal AG, Pillai A, Tiro J: Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11: e1001624.
- Preiss JC, Bokemeyer B, Buhr HJ, et al.: Aktualisierte S3-Leitlinie –„Diagnostik und Therapie des Morbus Crohn“ 2014. Z Gastroenterol 2014; 52: 1431–84.
- Mahid SS, Minor KS, Soto RE, et al.: Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462–71.
- Timmer A, Sutherland LR, Martin F: Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology 1998; 114: 1143–50.
- Kane SV, Flicker M, Katz-Nelson F: Tobacco use is associated with accelerated clinical recurrence of Crohn’s disease after surgically induced remission. J Clin Gastroenterol 2005; 39: 32–5.
- Johnson GJ, Cosnes J, Mansfield JC: Review article: smoking cessation as primary therapy to modify the course of Crohn’s disease. Aliment Pharmacol Ther 2005; 21: 921–31.
- Cosnes J, Carbonnel F, Beaugerie L, et al.: Effects of cigarette smoking on the longterm course of Crohn’s disease. Gastroenterology 1996; 110: 424–31.
- Andreas S, Batra A, Behr J, et al.: Tabakentwöhung bei COPD. Pneumologie 2014; 68: 237–58.
- Pox C, Aretz S, Bischoff SC, et al.: S3-Leitlinie Kolorektales Karzinom. Z Gastroenterol 2013; 51: 753–854.
- Sieg A, Hachmoeller-Eisenbach U, Eisenbach T: Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. Gastrointest Endosc 2001; 53: 620–7.
- Brenner H, Chang-Claude J, Seiler CM, et al.: Long-term risk of colorectal cancer after negative colonoscopy. J Clin Oncol 2011; 29: 3761–7.
- Rex DK, Cummings OW, Helper DJ, et al.: 5-year incidence of adenomas after negative colonoscopy in asymptomatic average- risk persons. Gastroenterology 1996; 111: 1178–81.
- Singh H, Nugent Z, Mahmud SM, et al.: Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol 2010; 105: 663–73; quiz 674.
- Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873–84.
- Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 146: 361–4.
- Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603–13.
- Chan AT, Giovannucci EL, Meyerhardt JA, et al.: Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Jama 2005; 294: 914–23.
- Lammert F, Neubrand MW, Bittner R, et al.: S3-Leitlinie zur Diagnostik und Therapie von Gallensteinen. Z Gastroenterol 2007; 45: 971–1001.
- Friedman GD, Raviola CA, Fireman B: Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol 1989; 42: 127–36.
- Attili AF, De Santis A, Capri R, et al.: The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology 1995; 21: 655–60.
- 40. McSherry CK, Ferstenberg H, Calhoun WF, et al.: The natural history of diagnosed gallstone disease in symptomatic and asymptomatic patients. Ann Surg 1985; 202: 59–63.
- Gracie WA, Ransohoff DF: The natural history of silent gallstones: the innocent gallstone is not a myth. N Engl J Med 1982; 307: 798–800.
- Sheth S, Bedford A, Chopra S: Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol 2000; 95: 1402–10.
- Friedman GD: Natural history of asymptomatic and symptomatic gallstones. Am J Surg 1993; 165: 399–404.
- www.choosingwisely.org/wp-content/uplo ads/2015/02/AASLD-Choosing-Wisely- List.pdf.
- Marrero JA, Ahn J, Rajender Reddy K: ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 2014; 109: 1328–47; quiz 348.
- Claudon M, Dietrich CF, Choi BI, et al.: Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34: 11–29.
- Shaked O, Siegelman ES, Olthoff K, et al.: Biologic and clinical features of benign solid and cystic lesions of the liver. Clin Gastroenterol Hepatol 2011; 9: 547–62. e1–4.
- Ehrl D, Rothaug K, Herzog P, et al.: „Incidentaloma“ of the liver: management of a diagnostic and therapeutic dilemma. HPB Surg 2012; 2012: 891787.
- Kuo YH, Wang JH, Lu SN, et al.: Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound 2009; 37: 132–7.
- Dignass A, Preiss JC, Aust DE, et al.: Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011. Z Gastroenterol 2011; 49: 1276–341.
- Steinhart AH, Ewe K, Griffiths AM, et al.: Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2003: Cd000301.
- Lindgren S, Lofberg R, Bergholm L, et al.: Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol 2002; 37: 705–10.
- Meyers S, Lerer PK, Feuer EJ, et al.: Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987; 9: 50–4.
- Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107: 1409–22.
Klug entscheiden in der Gastroenterologie
